<div class="js-c19-feed" data-post-type="document" id="c19-feed-anchor"><div class="row m-0 mb-1 px-1 border">
                    <div class="col-12 col-md-7 c19-feed__item px-1 py-2">
                      <h2 class="heading-sm"><a href="https://covid19.public-inquiry.uk/documents/inq000183828-rule-9-questionnaire-response-from-andrew-nelson-technical-advisory-group-cell-undated/" class="d-inline-block">INQ000183828 - Rule 9 Questionnaire Response from Andrew Nelson, Technical Advisory Group/Cell, undated.</a></h2>
                      <p>Rule 9 Questionnaire Response from Andrew Nelson, Technical Advisory Group/Cell, undated.</p>
                    </div>
                    <div class="col-12 col-md-5 c19-feed__item px-1 pb-2 pt-md-2">
                      <ul class="list-reset meta flow-content--sm">
                      <li><span class="label">Type: </span>Evidence</li><li><span class="label">Module: </span>Module 2B</li>
                      </ul>
                    </div>
                  </div><div class="row m-0 mb-1 px-1 border">
                    <div class="col-12 col-md-7 c19-feed__item px-1 py-2">
                      <h2 class="heading-sm"><a href="https://covid19.public-inquiry.uk/documents/inq000274116-witness-statement-of-dr-heather-payne-senior-medical-officer-for-womens-and-childrens-health-welsh-government-regarding-private-communications-dated-13-12-2023/" class="d-inline-block">INQ000274116 - Witness Statement of Dr Heather Payne, Senior Medical Officer for Women's and Children's Health, Welsh Government, regarding Private Communications, dated 13/12/2023.</a></h2>
                      <p>Witness Statement of Dr Heather Payne, Senior Medical Officer for Women's and Children's Health, Welsh Government, regarding Private Communications, dated 13/12/2023.</p>
                    </div>
                    <div class="col-12 col-md-5 c19-feed__item px-1 pb-2 pt-md-2">
                      <ul class="list-reset meta flow-content--sm">
                      <li><span class="label">Type: </span>Evidence, Witness Statement</li><li><span class="label">Module: </span>Module 2B</li>
                      </ul>
                    </div>
                  </div><div class="row m-0 mb-1 px-1 border">
                    <div class="col-12 col-md-7 c19-feed__item px-1 py-2">
                      <h2 class="heading-sm"><a href="https://covid19.public-inquiry.uk/documents/inq000260639-witness-statement-provided-by-ruth-marks-on-behalf-of-the-wcva-dated-01-09-2023/" class="d-inline-block">INQ000260639 - Witness Statement provided by Ruth Marks on behalf of the WCVA, dated 01/09/2023.</a></h2>
                      <p>Witness Statement provided by Ruth Marks on behalf of the WCVA, dated 01/09/2023.</p>
                    </div>
                    <div class="col-12 col-md-5 c19-feed__item px-1 pb-2 pt-md-2">
                      <ul class="list-reset meta flow-content--sm">
                      <li><span class="label">Type: </span>Evidence, Witness Statement</li><li><span class="label">Module: </span>Module 2B</li>
                      </ul>
                    </div>
                  </div><div class="row m-0 mb-1 px-1 border">
                    <div class="col-12 col-md-7 c19-feed__item px-1 py-2">
                      <h2 class="heading-sm"><a href="https://covid19.public-inquiry.uk/documents/inq000274118-witness-statement-of-thomas-smithson-civil-servant-welsh-government-regarding-private-communications-dated-13-12-2023/" class="d-inline-block">INQ000274118 - Witness Statement of Thomas Smithson, Civil Servant, Welsh Government, regarding Private Communications, dated 13/12/2023.</a></h2>
                      <p>Witness Statement of Thomas Smithson, Civil Servant, Welsh Government, regarding Private Communications, dated 13/12/2023</p>
                    </div>
                    <div class="col-12 col-md-5 c19-feed__item px-1 pb-2 pt-md-2">
                      <ul class="list-reset meta flow-content--sm">
                      <li><span class="label">Type: </span>Evidence, Witness Statement</li><li><span class="label">Module: </span>Module 2B</li>
                      </ul>
                    </div>
                  </div><div class="row m-0 mb-1 px-1 border">
                    <div class="col-12 col-md-7 c19-feed__item px-1 py-2">
                      <h2 class="heading-sm"><a href="https://covid19.public-inquiry.uk/documents/inq000183866-rule-9-questionnaire-response-from-dr-thomas-woolley-techincal-advisory-group-cell-undated/" class="d-inline-block">INQ000183866 - Rule 9 Questionnaire Response from Dr Thomas Woolley, Techincal Advisory Group/Cell, undated.</a></h2>
                      <p>Rule 9 Questionnaire Response from Dr Thomas Woolley, Techincal Advisory Group/Cell, undated.</p>
                    </div>
                    <div class="col-12 col-md-5 c19-feed__item px-1 pb-2 pt-md-2">
                      <ul class="list-reset meta flow-content--sm">
                      <li><span class="label">Type: </span>Evidence</li><li><span class="label">Module: </span>Module 2B</li>
                      </ul>
                    </div>
                  </div><div class="row m-0 mb-1 px-1 border">
                    <div class="col-12 col-md-7 c19-feed__item px-1 py-2">
                      <h2 class="heading-sm"><a href="https://covid19.public-inquiry.uk/documents/inq000274123-witness-statement-of-jo-trott-head-of-covid-19-project-team-welsh-government-regarding-private-communications-dated-14-12-2023/" class="d-inline-block">INQ000274123 - Witness Statement of Jo Trott, Head of Covid-19 Project Team, Welsh Government, regarding Private Communications, dated 14/12/2023.</a></h2>
                      <p>Witness Statement of Jo Trott, Head of Covid-19 Project Team, Welsh Government, regarding Private Communications, dated 14/12/2023.
</p>
                    </div>
                    <div class="col-12 col-md-5 c19-feed__item px-1 pb-2 pt-md-2">
                      <ul class="list-reset meta flow-content--sm">
                      <li><span class="label">Type: </span>Evidence, Witness Statement</li><li><span class="label">Module: </span>Module 2B</li>
                      </ul>
                    </div>
                  </div><div class="row m-0 mb-1 px-1 border">
                    <div class="col-12 col-md-7 c19-feed__item px-1 py-2">
                      <h2 class="heading-sm"><a href="https://covid19.public-inquiry.uk/documents/inq000183857-rule-9-questionnaire-response-from-professor-biagio-lucini-techincal-advisory-group-cell-undated/" class="d-inline-block">INQ000183857 - Rule 9 Questionnaire Response from Professor Biagio Lucini, Techincal Advisory Group/Cell, undated.</a></h2>
                      <p>Rule 9 Questionnaire Response from Professor Biagio Lucini, Techincal Advisory Group/Cell, undated.</p>
                    </div>
                    <div class="col-12 col-md-5 c19-feed__item px-1 pb-2 pt-md-2">
                      <ul class="list-reset meta flow-content--sm">
                      <li><span class="label">Type: </span>Evidence</li><li><span class="label">Module: </span>Module 2B</li>
                      </ul>
                    </div>
                  </div><div class="row m-0 mb-1 px-1 border">
                    <div class="col-12 col-md-7 c19-feed__item px-1 py-2">
                      <h2 class="heading-sm"><a href="https://covid19.public-inquiry.uk/documents/inq000183821-rule-9-questionnaire-response-from-dr-jonathan-mullins-techincal-advisory-group-cell-dated-14-03-2023/" class="d-inline-block">INQ000183821 - Rule 9 Questionnaire Response from Dr Jonathan Mullins, Techincal Advisory Group/Cell, dated 14/03/2023.</a></h2>
                      <p>Rule 9 Questionnaire Response from Dr Jonathan Mullins, Techincal Advisory Group/Cell, dated 14/03/2023.</p>
                    </div>
                    <div class="col-12 col-md-5 c19-feed__item px-1 pb-2 pt-md-2">
                      <ul class="list-reset meta flow-content--sm">
                      <li><span class="label">Type: </span>Evidence</li><li><span class="label">Module: </span>Module 2B</li>
                      </ul>
                    </div>
                  </div><div class="row m-0 mb-1 px-1 border">
                    <div class="col-12 col-md-7 c19-feed__item px-1 py-2">
                      <h2 class="heading-sm"><a href="https://covid19.public-inquiry.uk/documents/inq000239423-witness-statement-provided-by-tim-savage-on-behalf-of-armakuni-dated-7-august-2023/" class="d-inline-block">INQ000239423 - Witness Statement provided by Tim Savage on behalf of Armakuni, dated 7 August 2023.</a></h2>
                      <p>Witness Statement provided by Tim Savage on behalf of Armakuni, dated 7 August 2023.</p>
                    </div>
                    <div class="col-12 col-md-5 c19-feed__item px-1 pb-2 pt-md-2">
                      <ul class="list-reset meta flow-content--sm">
                      <li><span class="label">Type: </span>Evidence, Witness Statement</li><li><span class="label">Module: </span>Module 2B</li>
                      </ul>
                    </div>
                  </div><div class="row m-0 mb-1 px-1 border">
                    <div class="col-12 col-md-7 c19-feed__item px-1 py-2">
                      <h2 class="heading-sm"><a href="https://covid19.public-inquiry.uk/documents/inq000183823-rule-9-questionnaire-response-from-professor-ronan-lyons-techincal-advisory-group-cell-undated/" class="d-inline-block">INQ000183823 - Rule 9 Questionnaire Response from Professor Ronan Lyons, Techincal Advisory Group/Cell, undated.</a></h2>
                      <p>Rule 9 Questionnaire Response from Professor Ronan Lyons, Techincal Advisory Group/Cell, undated.</p>
                    </div>
                    <div class="col-12 col-md-5 c19-feed__item px-1 pb-2 pt-md-2">
                      <ul class="list-reset meta flow-content--sm">
                      <li><span class="label">Type: </span>Evidence</li><li><span class="label">Module: </span>Module 2B</li>
                      </ul>
                    </div>
                  </div></div>